BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Prostate Cancer Testing Market - A Global and Regional Analysis.

According to this study, the global prostate cancer testing market was valued at $5.24 billion in 2021 and is projected to reach $21.30 billion by 2032.

The following factors are responsible for the increase in demand for prostate cancer testing:
• Rising prevalence of prostate cancer globally
• Increasing number of prostate cancer screening and testing
• Government initiatives related to prostate cancer


The detailed study is a compilation of 10 market data tables and 177 figures spread through 223 pages.



Check out the detailed table of content here:
https://bisresearch.com/requestsample?id=1414&type=toc



Analyst’s Take on the Market Projection
According to Nitish Kumar, Principal Analyst, BIS Research, “Prostate cancer testing includes various tests being followed for past several years. The treatment starts with the prostate cancer screening that includes preliminary tests, i.e., prostate-specific antigen test and digital rectal exam (DRE). If prostate cancer is suspected based on the results of screening tests or symptoms and an elevated PSA test, the patient is referred to a urologist. To determine whether cancer has spread beyond the prostate, the following testing is undertaken, i.e., pre-biopsy test (biomarker test which is blood-based and urine-based biomarker) and imaging (mp-MRI (Multi-parametric Magnetic Resonance Imaging)), prostate biopsy, and post-biopsy procedures such as tissue-based biopsy”.

Request a FREE sample of this report here
https://bisresearch.com/requestsample?id=1414&type=download



Pre-Biopsy Test Type to Dominate the Prostate Cancer Testing Market Between 2021-2032
The prostate cancer testing market can be segmented by type into largely three categories. These are the pre-biopsy test, biopsy, and post-biopsy test.

According to the research conducted by BIS Research, the pre-biopsy test type dominated the prostate cancer testing market in 2021 with a magnum market share of 62.25%. The study further suggests that this trend is expected to continue during the forecast period of 2021-2032, where the pre-biopsy test type is expected to witness a CAGR of 14.15%.



Major Existing Industry Leaders in the Prostate Cancer Testing Market
The companies that are profiled have been selected based on input gathered from primary experts and analyzing company coverage, product portfolio, and market penetration. Some of the established names in the market are Abbott, Abcam plc., Agilent Technologies, Inc., Bio-Techne. (ExoDx), Cleveland Diagnostics, Inc., Danaher. (Beckman Coulter, Inc.), Exact Sciences Corporation, F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.), H.U. Group Holdings, Inc. (Fujeribio), mdxhealth, Siemens Healthcare GmbH, Myriad Genetics, Inc., NeoGenomics Laboratories, OPKO Health, Inc. (GenPath), and Veracyte, Inc.


Developments in Recent Years in the Global Prostate Cancer Testing Market

• In September 2022, Veracyte, Inc. announced the publishing of data in the Journal of the National Cancer Institute to demonstrate the company’s decipher prostate genomic classifier may help identify African American men with early, localized prostate cancer who are most likely to harbor more aggressive disease.
• In June 2021, Thermo Fisher Scientific announced submissions open for the Oncomine Clinical Research Grant program to support clinical research projects in oncology. The grant aims to provide funding for high-quality molecular profiling studies focusing on the impact of immune-based treatments for cancer patients.
• In August 2019, BioReference Laboratories, Inc. announced the selection by The IPA Association of America (TIPAAA) as its provider of laboratory services and to assist with data analytics for its members’ patients. The agreement is designed to enhance patient care and offers collaborative health management tools to TIPAAA members, which includes more than 667 medical organizations in 39 states. The members can have convenient access to BioReference’s comprehensive laboratory testing menu, including routine and specialty tests, as well as the 4Kscore for detecting aggressive prostate cancer.

Want to learn more about the latest trends in precision medicine? Speak to our analysts


Exclusive DeepTechTM MAP Healthcare by BIS Research:
U.S. Prostate Cancer Testing Market
Extensive Stage Small Cell Lung Cancer Market
Lung Cancer Genomic Testing Market


About BIS Research:
BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends which can disrupt the market dynamics in the near future. We publish more than 200 market intelligence studies annually that focus on several deep technology verticals.

Our strategic market analysis emphasizes on market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

BIS Research offers syndicate as well as custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscapes.


Contact:
Bhavya Banga
Email: [email protected]
BIS Research Inc.
39111 PASEO PADRE PKWY STE 313,
FREMONT CA 94538-1686
Visit our Blog @ https://bisresearch.com/news
Get Expert Insights @ https://community.insightmonk.com
Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research
Connect with us on Twitter@ https://twitter.com/BISResearch